Serine/arginine-rich splicing factor 7 regulates p21-dependent growth arrest in colon cancer cells by Saijo, Saki et al.
INTRODUCTION
The serine/arginine-rich splicing factor (SRSF) family, a family of
essential splicing regulators, comprises 12 evolutionarily conserved
and structurally related RNA-binding proteins (SRSF1-12) (31). The
family members contain one or two RNA-Recognition motif (RRM)
at the N-terminus and one SR domain, which mediates interaction
with other proteins, at the C-terminus. Each SRSF protein was dis-
covered as a pre-mRNA splicing factor in 1990s (14), and sub-
sequent studies have characterized them as the multifunctional
proteins in genome stability (25) and in gene expression through
histone modifications (29), mRNA elongation (28), mRNA poly-
adenylation (30), mRNA transport (35), and translation (34).
After the discovery of the SRSF family, two classical SRSF pro-
teins, SRSF1 (formerly SF2/ASF) and SRSF2 (formerly SC35),
have been extensively investigated to uncovered crucial roles of
these two proteins in cell cycle regulation, genome stability, and
translation as well as pre-mRNA splicing (13). Overexpressed
SRSF1 induced epithelial cell transformation through induction
of alternative splicing of BLC2 family, BIM and BIN1 (5). The loss
of SRSF1 or SRSF2 leads formation of mutagenic R loop structure,
resulting in G2/M cell cycle arrest associated with genome insta-
bility (25, 26). Reduction of SRSF3 led to the cell cycle arrest at G1
by downregulating expression of the G1-to-S checkpoint-related
genes (23). A subset of SRSF proteins are overexpressed in several
types of tumors, as evidenced by amplification of SRSF1 mainly
in breast cancers activated by the pro-oncogenic transcription fac-
tor Myc (4, 12), and enhanced expression of SRSF3 in ovarian and
colon cancers (8, 19). However, the distinct contribution of SRSF7
to cell growth or tumor progression has not been fully understood.
SRSF7 was cloned in 1994 (11) and identified as an mRNA export
regulator as well as a splicing factor. SRSF7 shuttles constantly be-
tween the nucleus and cytoplasm (10), and contribute to the export
of certain viral and cellular mRNAs through directly binding to
transporter 1 (TAP)/nuclear RNA export factor 1 (NXF1), an es-
sential mRNA export factor (16, 20, 21, 32). In addition, overexpres-
sion of SRSF7 enhanced the association of polyribosome with a
structured RNA sequence, termed the constitutive transport ele-
ment (CTE), which recruits TAP/NXF1 (36).
In this study, we showed that SRSF7 knockdown induced p21
(also known as p21WAF1/CIP encoded by cyclin-dependent kinase
inhibitor 1A (CDKN1A)). p21 is a well -known tumor suppressor
protein, which inhibits the activity of cyclin-dependent kinase 2
(CDK2) by interfering with phosphorylation of CDK2, leading to
cell -cycle arrest in response to various stimuli (1). The tumor sup-
pressor protein p53 mediates the cell -cycle checkpoint through
the activation of various growth inhibitory or apoptotic genes, in-
cluding the CDKN1A gene. The canonical p53-p21 axis of the G1/S
checkpoint pathway has a pivotal role in the DNA damage- induced
transactivation of CDKN1A gene expression. However, post- tran-
scriptional regulations, such as mRNA stability, translation, and
proteolytic degradation, are recognized as equally important in the
regulation of p21 expression.
The present study revealed that reduction of SRSF7 in colon can-
cer cells inhibited cell growth in association with p21 induction.
The SRSF7 knockdown-induced p21 induction was due to, at least
in part, increased stability of both CDKN1A mRNA and p21. These
findings provide new insights into the role of SRSF7 in cell growth.
MATERIALS AND METHODS
Cell culture.
HCT116 cells were cultured in Dulbecco’s Modified Eagle
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Medium (Nacalai Tesque, Kyoto, Japan) supplemented with 5%
(vol/vol) heat- inactivated fetal bovine serum and antibiotics at
37 in 5% CO2.
RNA interference.
We used small interference RNAs (siRNAs) (Nippon Gene,
Tokyo, Japan) targeting SRSF7 mRNA (#1, 5’ -GAAAGGGCUUU-
CAGUUAUU-3’ ; #2, 5’ -GGAUCGAGGUAUUUCCAAU-3’). A uni-
versal negative control (Nippon Gene) was used as a control siRNA.
HCT116 cells were treated with the indicated siRNAs at a final con-
centration of 10 nM using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Quantitative real-time reverse transcription-PCR (qPCR).
Total RNA was extracted from HCT116 cells using an RNAiso
plus (Takara, Otsu, Japan). One microgram of isolated RNA was
reverse-transcribed using ReverTra Ace reverse transcriptase
(Toyobo, Osaka, Japan). SRSF7 and CDKN1A mRNA levels were
measured using SYBR green master mix and the 7500 real - time
system (Applied Biosystems, Foster City, CA). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and β-actin (ACTB) mRNAs
were measured as internal controls for normalization. Using the
ΔΔCt method, the data are presented as the fold changes in mRNA
levels relative to those in control siRNA-treated cells. The follow-
ing primer sets were used for SRSF7 (forward, 5’ -GCGAAGAAG-
AAGCAGGTCACGGTCT-3’ and reverse, 5’ -TGCGTGAGCGAG-
AGTATCGCCTTCC-3’), for CDKN1A (forward, 5’ -TCACTGTCT-
TGTACCCTTGTGC-3’ and reverse, 5’ -GGCGTTTGGAGTGGT-
AGAAA-3’), for GAPDH (forward, 5’ -AGCCACATCGCTCAGAC-
AC-3’ and reverse, 5’ -AGCCACATCGCTCAGACAC-3’), and for
ACTB (forward, 5’ -ATTGCCGACAGGATGCAGA-3’ and reverse,
5’ -GAGTACTTGCGCTCAGGAGGA-3’). TissueScan tissue qPCR
arrays (HCRT103) including cDNAs from paired normal and tumor
tissues in 22 patients with adenocarcinomas of the colon were
obtained from OriGene Technologies (Rockville, MD), and SRSF7
levels in normal and tumor tissues were determined by qPCR.
SRSF7 levels were measured by the comparative ΔΔCt method
using ACTB mRNA as a control and expressed as values relative
to the normal samples.
Western blotting.
Whole-cell lysates were prepared in 1 x RIPA buffer (Cell
Signaling Tech., Danvers, MA) containing a protease and phos-
phatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The
extracted proteins were separated by SDS-PAGE and transferred
to a polyvinylidene difluoride membrane (BioRad, Hercules, CA).
After blocking with 5% non-fat dry milk, the membranes were incu-
bated overnight at 4 with a rabbit polyclonal anti -SRSF7 (1 : 1000
dilution ; Bethyl Laboratories, Montgomery, TX), anti -phospho-
CDK2 (1 : 1000 ; Cell Signaling Tech.), anti -CDK2 (1 : 1000 ; Cell
Signaling Tech.), anti -phospho-retinoblastoma protein (pRb) (1 :
1000, Cell Signaling Tech.), anti -Rb (1 : 1000, Cell Signaling Tech.),
anti -p21 (1 : 2000, Santa Cruz Biotech., Santa Cruz, CA), anti -p53 (1 :
1000, Cell Signaling Tech.), or anti -GAPDH (1 : 5000 ; Santa Cruz
Biotech.) antibody. The intensities of the bound antibodies were
quantified by using the Image J software (NIH, Bethesda, MD).
Cell cycle analysis
Cells in S phase were assessed by counting bromodeoxyuridine
(BrdU)-positive cells using an APC-BrdU Flow kit (BD pharmingen,
San Diego, CA) following the manufacturer’s instructions. Briefly,
after treatment with the indicated siRNAs for 24 or 72 h, cells were
incubated with 10 μM BrdU in the culture medium for 30 min at
37, harvested with Accutase (Nacalai), and washed twice with
cold PBS. These cells were fixed, permeabilized by BD Cytofix/
Cytoperm buffer for 15 min, and washed once with BD Perm/Wash
buffer. After incubation in BD Cytoperm Plus buffer for 10 min on
ice, the cells were washed again, re- fixed for 5 min at room tem-
perature, washed once, and treated with DNase for 1 h at 37 to
expose incorporated BrdU. After washing, the cells were incubated
with APC-conjugated anti -BrdU for 30 min at room temperature.
The cells were incubated in staining buffer containing 7-AAD for
20 min at room temperature. They were subjected to FACS analysis.
The cell cycle distribution was determined with a flow cytometer
(BD FACSverse system, BD). Data were analyzed using FlowJo
(Tree Star, Inc., Ashland, OR).
Reporter constructs.
For CDKN1A promoter activity assay, the 5’ flank of the human
CDKN1A gene was cloned into the pGL4.21 luciferase reporter
vector (Promega, Madison, WI). In brief, the first PCR was per-
formed using human genomic DNA as a template. The proximal
promoter region of CDKN1A (from -2688 to +31 bp) was amplified
using the following primer set : 5’ -AAAAACTCGAGGGCTGCCT-
CTGCTCAATAATGTTCT-3’ (forward, XhoI site is underlined) and
5’ -AAAAAAAGCTTACTGACTTCGGCAGCTGCTCACACC-3’
(reverse, HindIII site is underlined). The amplified product was
subcloned into the pGL4.21 vector using the XhoI and HindIII
restriction sites.
Gene expression and pathway analyses.
After treatment of HCT116 cells with SRSF7 siRNA #1 or control
siRNA for 48 h, total RNA was extracted as described above. After
the quality of the purified RNA was assessed, gene expression was
measured using a whole human genome microarray (SurePrint G3
Human GE 8 x 60K ; Agilent Technologies, Santa Clara, CA, USA)
as described previously (24). Microarray data were analyzed by
GeneSpring 11.5.1 (Agilent Technologies). The functional pathways
related to the set of differentially expressed genes were assessed
by the Ingenuity Pathway Analysis (IPA) (http : //www.ingenuity.
com). The probability of a relationship between each biological
function and the identified genes was calculated by Fisher’s exact
tests. The level of significance was set at a P -value of 0.05.
RESULTS
Role of SRSF7 in colon cancer cell growth.
First, we examined the expression of SRSF7 mRNA in colorectal
cancers, using 22 different cDNA libraries prepared from patients
with colorectal cancers (Figure 1a). The expression levels of SRSF7
mRNA varied depending on individual samples ; however, colorec-
tal cancer tissues expressed significantly higher levels of SRSF7
mRNA, compared with surrounding normal tissues.
Next, HCT116 cells were transfected with two different siRNAs
(#1 and #2) targeting SRSF7, and their growth was monitored. The
treatment with two different siRNAs for 48 h efficiently reduced
SRSF7mRNA (Figure 1b) and SRSF7 protein (Figure 1c) levels. As
shown in Figure 1d, both SRSF7 siRNA #1 and #2 significantly
suppressed cell proliferation 48 and 72 h after their transfection.
In particular, the growth was almost completely arrested with SRSF7
siRNA #1 (Figure 1d).
To determine how SRSF7 knockdown inhibited cell growth, the
cell cycle status was analyzed by FACS analysis after incubation
with BrdU. Since SRSF7 siRNA #1 more effectively suppressed cell
growth than SRSF7 siRNA #2 did, we subjected SRSF7 siRNA #1-
treated cells to FACS analysis. The percentage of BrdU-positive
cells in S phase was significantly reduced to9% at 24 h after
treatment with SRSF7 siRNA #1 compared with that of control
siRNA-treated cells (around 20%). At 72 h after transfection, the
percentage substantially decreased to2% in association with the
accumulation of cells in the G0/G1 phase. These results indicated
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that SRSF7 knockdown blocked the cell -cycle progression from
G1 to S phase.
Reduction of SRSF7 alters expression of cell cycle-related genes.
To elucidate the mechanism for the SRSF7 knockdown-induced
G1 arrest, we analyzed gene expression signatures after treatment
of HCT116 cells with SRSF7 siRNA #1 or control siRNA for 48 h.
Microarray analysis identified 4,499 genes whose expression dif-
feredtwofold between SRSF7 knockdown and control cells ; 2,285
and 2,214 genes were down- and up-regulated in SRSF7 knock-
down cells, respectively. IPA ranked “Role of BRCA1 in DNA Dam-
age Response” (P=2E-07, z-score=-1.091), “Cell Cycle : G1/S
Checkpoint Regulation” (P=9.4E-06, z-score=1.460), and “Cyclins
and Cell Cycle Regulation” (P=2.25E-05, z-score=-1.877) as the
top three canonical pathways related to the 4,499 affected genes
(Figure 2a). Notably, IPA suggested that the activation of p53/p21
pathways likely proceeded to repress expression of their target
genes including those encoding CDK2, E2F, and pRb (Figures 2a
Figure 1. SRSF7 knockdown induces G1 cell cycle arrest. (a) SRSF7mRNA levels in colorectal cancer tissues and surrounding normal tissues
from 22 patients were measured by qPCR using human colon cancer tissue qPCR Arrays (TissueScan, HCRT103). Values were normalized to ACTB
mRNA levels. (*P0.05 by paired t - test) (b) After treatment with 10 nM control siRNA, SRSF7 siRNA #1 or SRSF7 siRNA #2 for 48 h, the amounts
of SRSF7 and GAPDHmRNAs were determined by qPCR. Values are expressed as fold changes compared with control siRNA-treated cells (mean
SD, n=5). Significantly decreased compared with control siRNA-treated cells (#P0.01 by unpaired Student’s t - test). (c)Whole -cell lysates were
prepared from the cells treated as described in (b) and subjected to Western blotting using the SRSF7 antibody. GAPDH was served as a loading
control. (d) After treatment of HCT116 with 10 nM of SRSF7 siRNA #1 ( ), #2 ( ), or control siRNA ( ), the numbers of growing cells in 35-mm-
diameter culture dishes were counted by a hemocytometer at 0, 24, 48 and 72 h. Values represent meansSD, n=3. (*P0.05 or #P0.01 by ANOVA
and Bonferroni test) (e) After transfection with the indicated siRNAs for 24 or 72 h, HCT116 cells were labeled with 10 μM bromodeoxyuridine (BrdU)
for 30 min at 37, and the percentages of BrdU-positive cells were determined by FACS analysis (upper panels). Representative histograms of cell
cycle analysis of the siRNA-treated cells are shown in lower panels.
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and 2b), resulting in G1/S arrest after SRSF7 knockdown. On the
other hand, the expression of other genes encoding master regu-
lators of G1/S checkpoint (p27,CDK4 and CDK6) was not changed
in SRSF7 siRNA #1-treated cells (Figure 2b).
SRSF7 knockdown up-regulates expression of p21 in a p53-
independent manner.
Western blot analysis was employed to confirm the effects of
SRSF7 knockdown on the p53/p21 pathway. It should be noted that
SRSF7 knockdown induced p21 without any induction of p53. p21
has a high affinity for cyclin E/CDK2 complexes (15) and prevents
their activation (18). SRSF7 knockdown reduced the levels of phos-
phorylated CDK2 in association with decline of amounts of CDK2
protein itself. This was also in the case of pRb, a downstream target
of CDK2 ; SRSF7 knockdown decreased phosphorylated pRb levels
(Figure 3a).
p53 is a crucial activator of transcription of CDKN1A encoding
p21. We therefore re-examined whether SRSF7 knockdown could
p53- independently inhibit cell growth in association with the induc-
tion of p21 using p53-null (p53 -/- ) HCT116 cells (kindly provided
by Dr. Vogelstein). SRSF7 knockdown inhibited cell growth (Figure
3b) and induced p21 (Figure 3c), similarly as observed in wild- type
HCT116 cells.
SRSF7 knockdown stabilizes CDKN1A mRNA
qPCR showed that treatment of HCT116 cells with SRSF7 siRNAs
increased CDKN1AmRNA levels within 24 h, and its levels contin-
ued to increase at least up to 72 h (Figure 4a). To elucidate the
mechanism for this increase in CDKN1A mRNA levels, we first ex-
amined whether the reduction of SRSF7 stimulated transcription of
the CDKN1A gene. We cloned a luciferase reporter construct contain-
ing -2,688/+31 bp region of the human CDKN1A promoter and trans-
fected it into HCT116 cells using the pGL4.21 vector. The -2,688/
+31 bp region possessed the basal promoter activity of CDKN1A
(Figure 4b). Treatment with SRSF7 siRNA #1 rather significantly
suppressed the promotor activity by 30%, and SRSF7 siRNA #2 did
not affect it (Figure 4b), suggesting that SRSF knockdown may not
activate CDKN1A transcription. Next, we tested whether SRSF7
knockdown changed the degradation rate of CDKN1AmRNA. As
shown in Figure 4c, both SRSF7 siRNA #1 and #2 significantly
Figure 2. Cell cycle -related pathways affected by SRSF7 knockdown. (a) Canonical pathways affected by the 4,499 genes, whose mRNA levels
were changestwofold after SRSF7 knockdown, were analyzed using the Ingenuity Pathway analysis (IPA). The top 10 canonical pathways affected
are listed. The level of significance was set at a P value of 0.05 (threshold) by the Fisher’s exact test. (b) The G1/S checkpoint regulatory network
represented by the differentially expressed genes is prepared using IPA. Molecules encoded by up- and down-regulated genestwofold after SRSF7
knockdown are shown in red and green, respectively.
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increased the stability of CDKN1A mRNA. These results suggest
that the reduction of SRSF7 may increase p21 at least in part by
stabilizing CDKN1A mRNA. Levels of p21 are also known to be
regulated by protein degradation. We measured the stability of p21
in control - or SRSF7 siRNA #1-treated cells. In the presence of a
protein synthesis inhibitor, cycloheximide, p21 was rapidly de-
graded in the control cells, whereas SRSF7 siRNA #1 almost com-
pletely blocked the p21 degradation during the experimental period.
Thus, the reduction of SRSF7 increased p21 levels through stabi-
lizing both its mRNA and protein.
DISCUSSION
SRSF family members are well -known regulators of both consti-
tutive and alternative splicing reactions. We report here that SRSF7,
a member of the SRSF family, plays a crucial role in the G1-to-S-
phase progression through regulating p21 expression. It has been
shown that the deficiency of SRSF1 (25, 26) or SRSF2 (37) facili-
tates R- loop formation and this genomic instability causes G2/M
cell cycle arrest. On the other hand, SRSF3 knockdown induces G1
arrest in association with down-regulation of a group of genes
encoding G1/S checkpoint regulators, resulting in subsequent
induction of apoptosis (23). In addition, SRSF1 and SRSF3 binds
histone H3 in G2/M phase to displace heterochromatin protein 1
from mitotic chromosomes (29). Thus, each SRSF protein seems
to have distinct functions in the regulation of cell fate. In contrast
to SRSF1-3 examined, we could not detect any sign of DNA damage
response or induction of apoptosis in SRSF7 knockdown cells. IPA
analysis of the differentially expressed genes in SRSF7 knockdown
cells indicated the activation of p53/p21-dependent G1 arrest path-
way. However SRSF7 knockdown did not induce p53 protein. In-
stead, SRSF7 knockdown induced p21 not only in p53+/+ HCT116
cells but also in p53 -/- HCT116 cells, resulting in growth arrest of
both types of cells. Thus, the reduction of SRSF7 specifically in-
duces p21 in a p53- independent manner.
p21 belongs to the Cip/Kip family of CDK inhibitors that inhibit
cell cycle progression mainly by interfering with the cyclin E/CDK2
complex (17). The kinase complex-mediated G1-to-S phase tran-
sition requires cyclin E/CDK2 and cyclin D/CDK4/CDK6, both
of which cooperatively phosphorylate pRb and release E2F1 from
the pRb-repressor complex (6, 7). In SRSF7 knockdown cells,
CDK2 and pRb remained hypophosphorylated. CDKN1A mRNA
was up-regulated within 12 h, and p21 levels were abundantly in-
creased at least 24 h after treatment with SRSF7 siRNAs, suggest-
ing that the accumulation of p21 may be crucial for the growth
Figure 3. SRSF7 knockdown induces p21 in a p53- independent manner. (a) After treatment of HCT116 cells with 10 nM of the indicated siRNAs
for 24 or 48 h, amounts of CDK2, phosphorylated CDK2, pRb, phosphorylated pRb, p53 and p21 in these cells were measured by Western blotting
using GAPDH a loading control. The data shown are representative of three independent experiments. (b) After treatment of p53 -/- HCT116 cells
with 10 nM of SRSF7 siRNA #1 ( ), #2 ( ), or control siRNA ( ), numbers of growing cells in 35-mm-diameter culture dishes were counted by a
hemocytometer at 0, 24, 48, 72 and 96 h. Values represent meansSD, n=6. (*P0.05 or #P0.01 by ANOVA and Bonferroni test) (c) After treat-
ment of p53 -/- HCT116 cells with 10 nM of the indicated siRNAs for 24 or 48 h, amounts of p21 in these cells were measured by Western blotting using
GAPDH as a loading control. The data shown are representative of three independent experiments.
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inhibition in SRSF7 knockdown cells.
Although p21 expression is regulated mainly at the transcription
level, several recent studies have revealed more complicated, multi -
step mechanisms for the regulation of p21 expression than previ-
ously thought (1). Although SRSF7 knockdown increased CDKN1A
mRNA levels, it rather reduced the promoter activity of CDKN1A.
The increase in CDKN1AmRNA levels may be due to the increased
stability of CDKN1A mRNA after SRSF7 knockdown. We also con-
sidered the possibility that CDKN1A might produce a more stable
mRNA isoform through changing alternative splicing reaction.
Several mRNA isoforms are transcribed from the human CDKN1A
gene (ENSG00000124762). However only the protein coding mRNA
isoform (ENST00000244741) could be detected in SRSF7 knock-
down cells by RT-PCR or qPCR (data not shown).
Interestingly, compared with transcriptional or post- transcrip-
tional regulation of CDKN1A mRNA expression, the stability of p21
seems to be more important in the increased expression of p21
in SRSF7 knockdown cells (Figure 4d). p21 is an unstable protein
with a half - life of around 30 min. E3 ubiquitin ligase complexes
(SCFSKP2, CRL4CDT2 and APC/CCDC20) regulate the proteolysis of p21
Figure 4. SRSF7 knockdown increases stability of both CDKN1AmRNA and p21. (a) After treatment of HCT116 cells with 10 nM of the indicated
siRNAs for 24, 48 or 72 h, levels of CDKN1A mRNA were measured by qPCR using GAPDH mRNA as an endogenous quantity control. Values
(meansSD, n=6) are expressed as fold changes, compared with those of control siRNA-treated cells. (*P0.05 by ANOVA and Bonferroni test)
(b) Twenty - four hours after treatment of HCT116 cells with 10 nM SRSF7 #1, #2 or control siRNA, these cells were transiently transfected with a
luciferase reporter plasmid driven by the -2,688/+31 bp promoter fragment of CDKN1A (CDKN1A-pGL4.21) or a control plasmid (empty -pGL4.21)
for 24 h. Luciferase activities in these cells were measured using the Dual -Luciferase Reporter Assay System. Data are presented as the fold change
relative to the control plasmid transfected-cells. *Significantly decreased compared with control siRNA-treated cells (P0.05 by ANOVA and
Bonferroni test). (c) After treatment of HCT116 cells with control siRNA ( ), SRSF7 siRNA #1 ( ) or SRSF7 siRNA #2 ( ) for 48 h, they were
incubated in the presence of 2.5 μg/ml actinomycin D for the indicated times. Amounts of CDKN1A and ACTBmRNAs were measured by qPCR at
each time point. Percentages of remaining mRNAs are plotted. (d) After treatment of HCT116 cells with control siRNA ( ), SRSF7 siRNA #1 ( )
or SRSF7 siRNA #2 ( ) for 48 h, they were incubated in the presence of 100 μg/ml cycloheximide for the indicated times. Amounts of p21 in these
cells were measured by Western blotting using GAPDH as a loading control (left panel). Signal intensities of the p21 protein band are calculated
using GAPDH as a loading control by ImageJ software. Percentages of remaining p21 are plotted (right panel). CHX, cycloheximide.
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through the proteasome pathway (2, 3, 9, 33). Among the ligases,
the gene expression analysis suggested downregulated expression
of SCFSKP2mRNA in SRSF7 knockdown cells. We therefore meas-
ured SKP2 levels by Western blotting. However, SKP2 levels were
not changed after SRSF7 knockdown (data not shown). At present,
the mechanism for the inhibition of p21 degradation remains to be
elucidated.
SRSF7 was originally discovered as an mRNA export regulator
(11). SRSF7 recognizes CTEs of virus mRNAs through its RRM
domain, and contributes to translational activation of these mRNAs
as well as mRNA export of them (20, 36). A subset of RNA-binding
proteins, SRSF3 and RBM4, regulate translational activity of their
targeted mRNAs through binding to 5’UTR of them (22, 27). Like
these RNA-binding proteins, SRSF7 might regulate translational
activity of endogenous mRNAs, including CDKNA1A mRNA, as well
as virus mRNAs. Indeed, consensus sequences of SRSF7 binding
sites are existed within 5’UTR of CDKN1AmRNA. It is of interest
to determine whether SRSF7 regulates translational activity of p21
in SRSF7 knockdown cells. Further studies are needed to address
this issue.
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